Table 4 Obstetric and neonatal outcomes

From: Transdermal testosterone gel vs placebo in women with diminished ovarian reserve prior to in vitro fertilization: a randomized, clinical trial

Outcome

Testosterone

Placebo

Mean difference (95% CI)

P value

 

na

 

na

   

Gestational age at delivery (weeks)

14

37.8 ± 2.9

20

39.1 ± 1.6

−1.26 (−2.82 to 0.28)

0.11

  Singleton

11

38.6 ± 1.5

20

39.1 ± 1.6

−0.49 (−1.66 to 0.68)

0.40

  Twin

3

35.0 ± 4.7

 

-

-

-

Birth weight (g)b

18

2955 ± 789

19

3087 ± 438

−131 (−555 to 291)

0.53

  Singleton

12

3259 ± 483

19

3087 ± 438

172 (−172 to 516)

0.31

  Twin

6

2348 ± 968

 

-

-

-

     

Relative Risk (95% CI)

 

Mode of delivery No. (%)

      

  Vaginal

15

7 (46.7)

20

9 (45.0)

1.11 (0.54–2.26)

0.77

  CS

15

7 (46.7)

20

11 (55.0)

-

-

  Missing

15

1 (6.7)

 

-

-

-

Congenital anomaly, No. (%)b

18

-

20

-

-

-

Neonatal sex, No. (%)b

      

Female

18

9 (50.0)

20

10 (50.0)

1.00 (0.52–1.89)

1.00

Male

18

9 (50.0)

20

10 (50.0)

-

-

  1. Categorical outcomes compared using two-sided chi-square or Fisher exact test. Continuous outcomes compared using two-sided Student’s t test of Mann Whitney test. A two-sided P value < 0.05 was considered statistically significant. Results were not adjusted for multiplicity.
  2. aData were missing for some participants; the number included for each observation is indicated in column “n”.
  3. bThese items are reported including twin fetuses as separate measurements.